Source comparison
Melanotan-2 for Sexual Function Research: Clinical Trial Comparison
Wessells et al. (2000) 20 males, psychogenic ED 0.025mg/kg SC, single dose 80% erectile response within 2 hours MC4R agonism → dopamine release First human trial confirming central mechanism. No vascular changes on Doppler Molinoff et al. (2003) 271 males, mix
This comparison does not assign a generated winner or score.
- Wessells et al. (2000)
- 20 males, psychogenic ED
- 0.025mg/kg SC, single dose
- 80% erectile response within 2 hours
- MC4R agonism → dopamine release
- First human trial confirming central mechanism. No vascular changes on Doppler
- Molinoff et al. (2003)
- 271 males, mixed-origin ED
- 0.025mg/kg SC, on-demand over 6 months
- 64% improvement in IIEF scores
- MC4R/MC3R activation
- Sustained efficacy without tachyphylaxis. Effect maintained across repeated doses
- Diamond et al. (2004)
- 32 females, HSDD (hypoactive sexual desire disorder)
- 0.020mg/kg SC, twice weekly × 8 weeks
- 72% increase in satisfying sexual events vs baseline
- Central arousal pathway activation
- First trial confirming cross-sex mechanism. Women reported spontaneous desire increases
- King et al. (2019)
- 84 males, confirmed psychogenic ED
- 1.5mg SC vs sildenafil 50mg, head-to-head
- 68% MT2 vs 51% sildenafil functional erections
- CNS modulation vs peripheral PDE5 inhibition
- MT2 outperformed in non-vascular dysfunction. Sildenafil subjects with normal Doppler still failed response
- Ongoing Phase 3 (2024–2026)
- 450 subjects, mixed gender, arousal disorders
- Weight-tiered dosing, maintenance protocol
- Results pending (expected Q3 2026)
- MC4R-selective agonism without MC1R tanning
- Goal: FDA approval for sexual dysfunction indication. Avoiding pigmentation as primary concern